PDA

View Full Version : Articles of Interest

Pages : 1 2 3 4 5 6 7 8 9 10 11 12 [13] 14
  1. Sirolimus/Rapamycin
  2. GM-CSF as therapy
  3. Herceptin (Traztuzumab)
  4. Local therapy for metastases
  5. PET/CT Shows Tumor Response to Trastuzumab
  6. Bezielle (BZ101) oral botanical
  7. Altered serotonin physiology in human bc favors paradoxical growth and cell survival
  8. HER2 Status Predicts Recurrence of Small Breast Cancers
  9. Activin/Nodal signaling results in invasive bc cells arising from non-invasive bc
  10. Hearing sensitivity in women following chemotherapy treatment for breast cancer
  11. Immediate Postmastectomy Reconstruction Tied to Better Breast Cancer Survival
  12. pRb loss predicts good outcome in triple negative breast cancer
  13. Ku proteins contribute to ERBB2 overexpression in breast cancer
  14. Vitamin D
  15. Pertuzumab
  16. mTOR inhibitors
  17. Pain From Breast Cancer Treatment Can Linger For Years, Study Finds
  18. GcMAF: vitamin D-binding protein-derived macrophage-activating factor
  19. Trigonelline stimulates ER (roasted coffee ingredient)
  20. Glucocorticoids
  21. HDAC Histone deacetylation inhibitors
  22. Anthracycline Cardiotoxicity Appears Limited in Breast Cancer in the Short Term
  23. USPSTF Issues New Breast Cancer Screening Guidelines
  24. Specialized Radiation Offers No Survival Benefit in Early Breast Cancer
  25. Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor in BC CTC's
  26. Data on Off-Label Targeted Cancer Drugs More Plentiful Than Helpful
  27. Growth Colony stimulation as chemo suppport
  28. Study: Discriminatory Accuracy of Prognosis Calculation of Adjuvant!
  29. JX-593: targeted and armed oncolytic and immunotherapeutic poxviruse
  30. Gemcitabine
  31. Sunitinib
  32. Chemo Combinations/sequences with oomph
  33. Neuropathy
  34. Temporal concurrence of vasculitis and cancer: a report of 12 cases.
  35. Anti-prolactins
  36. Aloe
  37. Mucositus
  38. Determining Her2 status
  39. Fever therapy
  40. Managing cardio-toxicity
  41. Vitamin C
  42. Taxol treatment can result in delayed chronic neuropathy
  43. Novel Biomarkers May Enhance Cancer Therapy (HER2+ covered)
  44. Opiates/Opioids
  45. Brain mets
  46. Estrogen Receptor-Alpha, Breast Cancer Patients And Tamoxifen Response
  47. Trastuzumab Prolongs Survival in HER2+ Metastatic Breast Cancer
  48. Insulin potentiated therapy (IPT)
  49. What is skin metastasis?
  50. Fasting to enhance chemo
  51. Treatment Resistance: Preventing, Reversing
  52. Mammography May Increase Breast Cancer Risk In Some High-Risk Women
  53. Medial tumor localization in breast cancer--an unappreciated risk factor?
  54. Chloroquine (s)
  55. Combining Nanotubes And Antibodies For Breast Cancer 'Search And Destroy' Missions
  56. Elastography Imaging During Breast Ultrasound Reduces Unnecessary Biopsy Rate
  57. Serum calcium levels are elevated among women with untreated postmenopausal breast ca
  58. Fucoidan
  59. Histamine
  60. Navelbine
  61. Cancer Rehab: reconditioning to resume therapy
  62. Neoplastic meningitis (spinnal mets)
  63. Prolonged exposure to passive smoke may increase breast cancer risk
  64. Decline In Breast Cancer: Not Just Because Of Hormone Therapy
  65. CDK inhibitors as potential therapeutics for ER+/ and/or Her2+ bc
  66. Single-fraction schedules of Radiotherapy for Painful Bone Mets Underutilized
  67. Platinum and Bisplatinates
  68. Pixantrone (anthracycline with less cardiac impact)
  69. BC progression model recapitulates hypermethylation events associated w/premalignacy
  70. Life as an oncologist
  71. ER+ issues
  72. Transforming Growth Factor Beta May Control Breast Cancer Metastasis
  73. Do not read Tololos messages
  74. Grapefruit juice
  75. Milk thistle
  76. Poorer Prognosis for Heavy Women With Breast Cancer
  77. Tamoxifen following chemotherapy improves breast cancer outcome
  78. Specialized Radiation Offers No Survival Benefit in Early Breast Cancer
  79. T-DM1 Shrinks Tumors
  80. Diagnosing Breast Cancer: Needle Biopsy Best?
  81. Balance is everything - Her2+ mentioned
  82. Chemo brain research results
  83. Novel breast tissue feature linked to breast cancer risk
  84. DHA may improve breast cancer chemotherapy outcome
  85. Cranberries
  86. Apples
  87. Hypoxia-Inducible Factor (HIF)
  88. Her2-like & Basal like Genotype BC are more likely to respond to chemo
  89. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
  90. Leaving Home Early: Reexamination of the Canonical Models of Tumor Progression
  91. Cancer Center Ads Use Emotion More Than Fact
  92. Old Ideas Spur New Approaches in Cancer Fight
  93. Stellate Ganglion Block for Severe Hot Flashes
  94. Extended Aromatase Inhibitor Therapy Warranted In Premenopausal Breast Cancer
  95. Artemisinin (anti-malarial, anti-cancer)
  96. Vitamin E
  97. Bone mets
  98. PREDICT: a new UK prognostic model for breast cancer survival
  99. Physician Expectations of Treatment Outcomes from Whole Brain Radiation
  100. TEAM Trial: 5 Years of Aromatase Inhibitor Equal to Sequential Therapy
  101. Acupuncture vs Venlafaxine for Hormone-Therapy−Induced Hot Flashes
  102. Investigational Agent Reduces Tumor Resistance To Breast Cancer Therapy
  103. A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
  104. The rapidly changing management of metastatic breast cancer
  105. An open conversation on metastatic breast cancer
  106. Pomegranate
  107. Mango
  108. Letrozole (Femara)
  109. supplement combinations
  110. Lung mets
  111. Ashwagandha (Withania somnifera)
  112. Cyclophosphamide
  113. Nigella Sativa (black cumin)
  114. Ertumaxomab
  115. Aryl-Hydrocarbon Receptor (AhR)
  116. PIPKI Gamma modulates invasion and proliferation; correlates with Her2+ and ER-
  117. Developing a gene expression profile to detect bc in peripheral blood
  118. Green tea polyphenol sensitizes bc cells to paclitaxel in mice
  119. Risk of Breast Cancer Death Higher in Patients on Paroxetine and Tamoxifen
  120. Testosterone, Vitamin D May Improve Aromatase Inhibitor Joint Problems
  121. Motherwort
  122. Hyperthermia for Breast Cancer
  123. Chemo+endocrine, endocrine + endocrine
  124. Editorial on bc stem cell markers
  125. Exemestane (Aromasin)
  126. acute myeloid leukemia (AML)
  127. Researches find Cyclin D1 required for self-renewal of Her2+ bc cells in mice
  128. HER2, TOP2A, and TIMP-1 and Responsiveness to Anthracyline tx
  129. Capsaicin (red pepper)
  130. Capecitabine (Xeloda)/5FU
  131. looking for an article on radiation
  132. Liver mets
  133. Antiangiogenic agents
  134. Research/study issues
  135. Honokiol (from magnolia)
  136. Garcinol/Garcinia indica
  137. Resveratrol
  138. Glucosamine
  139. Personalized Cancer Care Off to Slow Start (Questions Tamoxifen CYP2D6 testing)
  140. Cocoa
  141. Second solid cancers after breast cancer not linked to radiotherapy
  142. FDA Approves Lapatinib/Letrozole Combination for Advanced Breast Cancer
  143. Neoadjuvant Trastuzumab Benefits Women With HER2+ Inflammatory or Locally Advanced BC
  144. Finnish treatment breakthrough reduces breast cancer deaths by a third
  145. Lack of Evidence for Fracture Prevention in Early Breast Cancer Bisphosphonate Trials
  146. Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate:The SABRE Trial
  147. Salmonella
  148. Personalized Cancer Care Off to Slow Start
  149. Pleural effusions
  150. Antibiotics
  151. Pertuzumab Useful for Trastuzumab-Resistant HER2-Positive Breast Cancer
  152. Prolactin Blocks Oncogene Associated With Poor Prognosis In Breast Cancer
  153. Chemoresistance
  154. Review of Advances in tx for Her2+ metastatic bc
  155. Radiation
  156. Seliciclib/Roscovitine
  157. Elephant's foot (Elephantopus scaber L)
  158. Promotion of variant human mammary epithelial cell outgrowth by ionizing
  159. Familial relative risks for breast cancer by pathological subtype
  160. 10-Year Results of Hypofractionated Radiation for Breast Cancer
  161. Should Oncologists Test for CYP2D6 Before Prescribing Tamoxifen?
  162. Radiation Oncologists Announce Six-Point Plan for Safer Radiotherapy
  163. Proton pump inhibitors (PPI)
  164. Selenium
  165. Chemosensitivity prediction
  166. Master Gene SRC-3 Enables Breast Cancer Growth, Invasion
  167. Survival, multi-lineage potency of bc initiating cells treated with rx
  168. Aspirin Benefit Seen in Existing BC
  169. Cancer origins (theories and research)
  170. Blocking EGFR receptor sensitizes bc cells to Her2 therapy
  171. 'Revolutionary' DNA Test for Cancer Hailed
  172. Boron (Boric acid)
  173. Vitamin D Kills Breast Cancer Cells
  174. Significant Effect of Polymorphisms Clinical Outcomes of Tamoxifen Therapy
  175. Bitter Melon Extract Attacks Breast Cancer Cells
  176. Scientists Unlock Key To Tamoxifen Resistance
  177. 2009 San Antonio Breast Cancer Symposium: Potentially Practice-Changing Studies, Pt 1
  178. 2009 San Antonio Breast Cancer Symposium: Potentially Practice-Changing Studies, Pt 2
  179. How to stay sane fighting cancer
  180. FDA show by John Stossel
  181. Lasofoxifene Helps Reduce Risk Of Bone Fractures, BC, Heart Disease And Stroke
  182. Sentinal Node Micromets linked to pooer BC Survival
  183. Gene test predicts effectiveness of Paclitaxel
  184. Researchers find no link between Cox2 inhibitor use and reduced bc risk
  185. Bitter melon/Karela (Momordica charamtia)
  186. Personalized Blood Test Can Track Tumor-Specific Markers After Therapy
  187. Miscellaneous side effects
  188. The role of soy on breast cancer risk and survival
  189. New way tx her2...
  190. Osteoporosis Drugs Are Associated With A Decrease In Risk Of Breast Cancer
  191. "Terrorist Cells" in Mar. 15, 2010 Forbes Mag.
  192. Lovastatin (a statin) has potential to reduce growth of bc cells
  193. Test for chemo sensitivity based on DNA repair proteins
  194. Primary Care Providers Uneasy on Cancer Survivorship Care
  195. Financial Hardship: A Frequent Side Effect of Cancer
  196. Green Tea/epigallocatechin-3-gallate (EGCG)
  197. Thiamine (Vitamin B-1) supplementation and cancer
  198. New trial to test Malaria drug on DCIS
  199. Risk of Recurrent Disease in HER2-Positive Patients
  200. Aspiration of Breast Lumps Reviewed
  201. Genetic variation in ER metabolic pathway not correlated with breast density
  202. Mapping proteomic pathways in MBC to tailor treatment
  203. 3-D ultrasound dx bc in dense breasts
  204. Familiar Risk related to tumor subtype
  205. From the NEJM: The Missing Voice of Patients in Drug-Safety Reporting
  206. From the NEJM: Individual Genomes on the Horizon
  207. Coexpression of HSP90 & PI3K or expression of HSP90 w/loss of PTEN predicts RFS in H2
  208. interesting article on protein signaling....
  209. Next Generation...
  210. Bad news on biphosphonates for longer than four years use...
  211. BC mets, tau, and Taxol
  212. Cancer and the Media
  213. Breast Cancer Treated by Freezing Tumors
  214. Tests for genes don't predict breast cancer better
  215. Liposomal taxanes en route
  216. Blocking Gene Ages Cancer Cells (skp2)
  217. Radioactive seeding could replace wire localization for bc surgery
  218. Entrapernurial Approach to Curing BC
  219. NIH studying progesterone to treat traumatic brain injuries
  220. Probe molecules give early answer to tx effectiveness
  221. Pertuzumab plus trastuzumab for Her2+ MBC
  222. Biomarkers Consortium Launches Adaptive Trial to Test Targeted Breast Cancer Drugs
  223. BC mortality in organised mammography screening in Denmark: comparative study
  224. Effect of Aromatherapy Massage in Patients with Breast Cancer
  225. From the NEJM: Bisphosphonates and Fractures of the Femur
  226. next generation of cancer research
  227. Use of Some SSRIs With Tamoxifen Increases Mortality in Breast Cancer Patients
  228. Targeting Signal Transduction Pathways in MBC: A Comprehensive Review
  229. CEP17 seems to predict anthracycline benefit
  230. Serum HER and EGFR testing
  231. Beta Blockers May Slow Spread of Breast Cancer
  232. Pemetrexed (Alimta)
  233. Ukrain/Celandine
  234. Treating the Her2-Positive Breast Cancer Patient
  235. New Research on Tamoxifen Resistance
  236. Review Paper on Signaling Pathways; Her2+ and ER+ discussed
  237. Identification of Subtypes in Her2+ BC Reveals a Gene Signature Prognostic of Outcome
  238. Locoregional Recurrence Remains Strong Outcome Predictor 10 Years After Lumpectomy
  239. Berberine/goldenseal
  240. Patient/Doctor Expectations of Metastatic Breast Cancer Treatments at Odds
  241. Longer Breastfeeding linked to More Aggressive Breast Cancer
  242. Can Metastatic Breast Cancer Be Cured?
  243. ZIOPHARM Commences Oral Indibulin Phase I/II Trial In Breast Cancer
  244. New Research in UK promising
  245. Workforce Shortages in Breast Imaging: Impact on Mammography Utilization
  246. Can Herceptin Wipe Out Cancer Stem Cells?
  247. Tykerb Can Reverse Herceptin Resistance
  248. Questions re HER2 Testing
  249. MicroRNA Responsible for Herceptin Resistance
  250. Sulforaphane (from broccoli)